Christian Callebaut

Also affiliated with Gilead Sciences (United States)

Immunology and MicrobiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

3in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 3 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 6 papers. Top paper: “Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial”.

Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial

The Lancet(2020)10.1016/s0140-6736(20)31065-5

N/A

13.0DataRank · unranked

427 citations

Jean-Michel Molina, Melanie A Thompson, Peter L Anderson, Karam C Mounzer, Joss J De Wet +19 more

Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results

JAIDS Journal of Acquired Immune Deficiency Syndromes(2017)10.1097/qai.0000000000001350

N/A

0.716DataRank · unranked

117 citations

Melanie Thompson, Paul E. Sax, Bernhard Haas, Cheryl McDonald, David A. Wohl +10 more

Rare emergence of drug resistance in HIV-1 treatment -naïve patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide

HIV Clinical Trials(2016)10.1080/15284336.2016.1142731

N/A

0.416DataRank · unranked

15 citations

Kathryn M. Kitrinos, Marshall Fordyce, Scott McCallister, Michael D. Miller, Christian Callebaut +1 more

Antiviral Activity of Lenacapavir Against Human Immunodeficiency Virus Type 2 (HIV-2) Isolates and Drug-Resistant HIV-2 Mutants

The Journal of Infectious Diseases(2023)10.1093/infdis/jiad562

N/A

0DataRank · unranked

16 citations

Dana N. Raugi, Robert S. Nixon, Moussa Seydi, Nicolas Margot, Christian Callebaut +43 more

HIV-1 envelope diversity and sensitivity to broadly neutralizing antibodies across stages of acute HIV-1 infection

AIDS(2023)10.1097/qad.0000000000003792

N/A

0DataRank · unranked

8 citations

Lisa Selzer, Brian Moldt, Aiyappa Parvangada, Jiani Li, Jintanat Ananworanich +9 more

HIV-1 envelope diversity and sensitivity to broadly neutralizing antibodies across stages of acute HIV-1 infection

UNC Libraries(2025)10.17615/zr4j-dk18

N/A

0DataRank · unranked

1 citations

Lisa Selzer, Joshua C. Cyktor, Aiyappa Parvangada, Joseph J. Eron, Laurie A. VanderVeen +9 more